Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Down 5.4% – Should You Sell?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares dropped 5.4% during trading on Tuesday . The stock traded as low as $134.46 and last traded at $134.31. Approximately 633,454 shares traded hands during mid-day trading, a decline of 10% from the average daily volume of 704,698 shares. The stock had previously closed at $142.02.

Analysts Set New Price Targets

Several research firms have weighed in on JAZZ. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Piper Sandler reaffirmed an “overweight” rating and issued a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Buy” and a consensus price target of $187.71.

Jazz Pharmaceuticals Stock Performance

The company has a market capitalization of $7.68 billion, a PE ratio of 17.80, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The business’s fifty day moving average is $132.19 and its two-hundred day moving average is $122.29.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,736 shares of company stock worth $4,022,825. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $25,000. Quadrant Capital Group LLC grew its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 101 shares during the period. Elequin Capital LP increased its holdings in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 183 shares during the last quarter. CoreFirst Bank & Trust bought a new position in Jazz Pharmaceuticals in the fourth quarter worth approximately $28,000. Finally, Allianz SE purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $29,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.